TABLE 3.
Baseline patient and disease characteristics: progression vs. nonprogression cohort
| Progression n = 23 (%) | Nonprogression n = 47 (%) | P-value | |
|---|---|---|---|
| Gender | — | — | 0.763 |
| Male | 16 (70) | 31 (66) | — |
| Female | 7 (30) | 16 (34) | — |
| Median age at initial diagnosis (range) | 31 (15–57) | 32 (12–65) | 0.945 |
| Mean BMI (SD) | 24.8 ± 3.6 | 24.6 ± 4.4 | 0.885 |
| Secondary illness | |||
| Arterial hypertension | 8 (35) | 10 (21) | 0.225 |
| Diabetes | 2 (9) | 1 (2) | 0.203 |
| Overlap syndrome with | |||
| AIH | 4 (17) | 1 (2) | 0.020 |
| Presence of IBD | 16 (70) | 33 (70) | 0.956 |
| Ulcerative colitis | 15 (65) | 27 (57) | — |
| Crohn’s disease | 0 (0) | 5 (11) | — |
| Undetermined | 1 (4) | 1 (2) | — |
| UDCA a | 23 (100) | 47 (100) | — |
| Median number of performed ERCPs per patient (range) | 10 (4, 20) | 7 (2, 25) | 0.015 |
| Stenosis amenable for intervention at initial ERCP | 17 (74) | 40 (85) | 0.258 |
| Manifestation a : | — | — | 0.311 |
| Exclusively intrahepatic | 2 (9) | 10 (22) | — |
| Exclusively extrahepatic | 3 (13) | 3 (7) | — |
| Intrahepatic and extrahepatic | 18 (78) | 33 (72) | — |
| Affection of the biliary tract system b : | — | — | 0.716 |
| Right-sided | 3 (15) | 5 (12) | — |
| Left-sided | 3 (15) | 10 (24) | — |
| Both | 14 (70) | 27 (64) | — |
| Median baseline laboratory parameters (Min-Max) | |||
| Bilirubin [mg/dL] | 0.7 (0.5, 4.4) | 0.8 (0.2, 4.7) | 0.549 |
| ALT [U/L] | 83 (28, 232) | 54 (14, 456) | 0.401 |
| AST [U/L] | 66 (25, 115) | 47 (18, 246) | 0.468 |
| ALP [U/L] | 261 (70, 626) | 184 (61, 798) | 0.410 |
| GGT [U/L] | 302 (38, 956) | 175 (17, 1276) | 0.458 |
| Creatinine [mg/dL] | 0.8 (0.4, 1) | 0.8 (0.5, 1.2) | 0.696 |
| INR | 1 (0.9, 1.1) | 1 (0.9, 1.2) | 0.763 |
Notes: Data are n (%) of patients if not indicated otherwise. The percentages were rounded and may not sum 100%. Significant results (P<0.05) are shown in bold type.
Laboratory reference values: Reference values: Bilirubin < 1.2 mg/dL, ALT < 31 U/L, AST 35 U/L, ALP 35–105 U/L, GGT 5–36 U/L, creatinine 0.5–0.96 mg/dL, INR 0.9–1.25
Manifestation of stenosis was analyzed in 69 patients; 23 patients in the progression cohort and 46 patients in the nonprogression cohort.
Affection of the biliary tract system was analyzed in 62 patients; 20 patients in the progression cohort and 42 patients in the nonprogression cohort.
Abbreviations: AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; ERCP, endoscopic retrograde cholangiopancreatography; GGT, gamma-glutamyl transferase; IBD, inflammatory bowel disease; INR, international normalized ratio; PBC, primary biliary cholangitis; UDCA, ursodeoxycholic acid.